Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA ® (pembrolizumab)

Dateline City: WILMINGTON, D.E.& KENILWORTH, N.J.Additional pivotal studies evaluating Incyte ’s IDO1 inhibitor in combination with Merck’s anti-PD-1 therapy in patients with non-small cell lung, renal, bladder and head and neck cancers expected to start in 2017WILMINGTON, D.E.& KENILWORTH, N.J.–Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the decision to advance the clinical development program investigating the combination of epacadostat, Incyte ’s investigational oral selective IDO1 inhibitor, with KEYTRUDA® (pembrolizumab), Merck ’s anti-PD-1 therapy.Language: Englishread more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news